CD5 and autoimmune disease: It is likely that FDA approval will come first for the use of anti-CD5 and anti-CD7 CAR T cell therapies for T cell leukemias and lymphomas; however, this could help pave the way for its future use in treating patients with severe T cell-mediated autoimmune diseases.